Syndax Pharmaceuticals Inc 8-K

What Happened

• On April 30, 2026, Syndax Pharmaceuticals, Inc. announced its financial results for the quarter and year ended March 31, 2026 and filed a Current Report on Form 8-K (Item 2.02) to disclose the update. The company furnished a press release and a corporate presentation as Exhibits 99.1 and 99.2 to the filing. The report was signed by CEO Michael A. Metzger.

Key Details

• Filing date: April 30, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter and year ended March 31, 2026.
• Exhibits furnished: 99.1 (press release, dated April 30, 2026) and 99.2 (corporate presentation, dated April 30, 2026).
• Authorized signature: Michael A. Metzger, Chief Executive Officer.

Why It Matters

• This 8-K signals Syndax has released its latest quarterly and full‑year financial results; those details (revenue, expenses, cash position, guidance or operational updates) are in the attached press release and presentation. Retail investors should review Exhibits 99.1 and 99.2 for the actual financial figures and any management commentary, since the Form 8-K itself references but does not include the numeric results.